Jakafi ruxolitinib regulatory update

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) and Novartis both estimate that Orphan drug Jakavi ruxolitinib will cost the German statutory health insurance funds (GKV) more than €50 million per year. Thus, the myelofibrosis drug is likely...